arned in 2009 and 2010 resulted from the recognition of a portion of the $35 million, upfront, non-refundable license fee under the Bayer agreement and the related reimbursement by Bayer of third-party development costs. In addition, in 2010, the Company recognized $15.0 million in revenue for the achievement of the first milestone, as well as approximately $0.4 million in sponsored research revenue, under the license agreement with Bayer.
For the three and twelve months ended December 31, 2010, total operating expenses increased to $17.8 million and $68.6 million, respectively, from $14.4 million and $52.9 million for the same periods in 2009. Total operating expenses for the three and twelve months ended December 31, 2010 included non-cash stock-based compensation charges of $1.8 million and $10.8 million, or $0.08 per share and $0.49 per share, respectively, as compared to charges of $1.4 million and $5.8 million, or $0.08 per share and $0.32 per share, respectively, for the same periods in 2009. These increased charges were primarily in connection with the departure of certain employees during the third quarter of 2010. The increase in total operating expenses between the 2009 and 2010 periods was primarily a result of an increase in research and development expense due mainly to the continued development and progression of our clinical and preclinical programs, as well as the above-described increase in non-cash, stock-based compensation expense.
Net loss for the three and twelve months ended December 31, 2010 was $0.6 million and $41.6 million, or $0.03 per share and $1.91 per share, respectively, compared to a net loss for the same periods in 2009 of $6.3 million and $30.9 million, or $0.34 per share and $1.70 per share, respectively. The decrease in net loss between the three-month periods and the increase in net loss between the twelve-month periods were due primarily to the revenue and operating expen
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE Ardea Biosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium2
. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting3
. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference4
. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools5
. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference6
. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors7
. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference8
. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act9
. Ardea Biosciences to Present at Two Upcoming Investor Conferences10
. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients11
. Ardea Biosciences Prices Public Offering of Common Stock